Loading search results
Survibase
Sponsor study identifier
observational
20,000
1 country
1
Study Start
November 27, 2020
Actual (reported)Primary Completion
January 4, 2041
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
January 4, 2041
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The first Intestinal Vascular Emergency Unit (SURVI), with the institutional support of AP-HP, opened on 4 January 2016, within the Paris-Nord Val de Seine University Hospital Group. This intensive care is dedicated to the management of mesenteric ischemias (acute mesenteric ischemias, chronic mesenteric ischemias) and Intestinal Vascular Diseases Without Ischemia. The organisation of this type of dedicated centre, combining advances in resuscitation, interventional radiology and knowledge of intestinal vascular diseases, has led to a radical change in the prognosis for acute mesenteric ischaemia with a survival rate of over 80% and an intestinal resection rate of less than 40%. Acute mesenteric ischaemia (AMI) is characterised by the combination of digestive distress and vascular insufficiency: occlusive (thrombosis, embolism, arterial, venous) or non-occlusive (low flow or vasospasm). The vital prognosis is catastrophic in the absence of treatment (the mortality rate of an intestinal infarction is almost 100% without treatment), and the functional and anatomical after-effects are major for the survivors. Many intestinal vascular diseases have been identified as providing acute and chronic mesenteric ischaemia. The nosological framework of these diseases is broad, ranging from constitutional diseases of the vessels (collagenosis, arcuate ligament syndrome) to acquired diseases of a thrombophilic, cardiac, degenerative, autoimmune, iatrogenic, traumatic nature... The rarity of these diseases (with the exception of atherosclerotic disease, the incidence of which is increasing with the ageing of the population) makes their level of knowledge insufficient. The natural history of vascular diseases without ischaemia (rate of acute and chronic mesenteric ischaemia, mortality rate, resection rate...) is currently not described. The construction of a longitudinal observational cohort is necessary for the prevalence of ischaemic complications and predictive factors.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 4, 2041
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 27, 2020
Actual (reported)December 18, 2020
Actual (reported)February 9, 2021
Actual (reported)January 4, 2041
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
January 4, 2041
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
mortality of Intestinal Ischemia
To study the prognosis of Intestinal (acute and chronic) Ischemia and Vascular Diseases (IIVD) at 1 year in terms of mortality.
1 year
mortality of Intestinal Ischemia
To study the prognosis of Intestinal (acute and chronic) Ischemia and Vascular Diseases (IIVD) at 5 years in terms of mortality.
5 years
Vascular Diseases (IIVD)
To study the prognosis of Intestinal (acute and chronic) Ischemia and Vascular Diseases
1 year
Vascular Diseases (IIVD)
To study the prognosis of Intestinal (acute and chronic) Ischemia and Vascular Diseases
5 years
Describe the prevalence of IIVD
1 year
Describe the prevalence of IIVD
5 years
Study mortality and its associated factors of IIVD
1 year
Study mortality and its associated factors of IIVD
5 years
Study the risk of intestinal resection of IIVD and its associated factors. Among resected patients, describe the incidence of short intestinal syndrome and dependence on parenteral nutrition
1 year
active patient file of the SURVI service
Olivier CORCOS
Clichy, 92110, France
First Submitted
December 18, 2020
First Posted
February 9, 2021
Study Start
November 27, 2020
Actual (reported)Primary Completion
January 4, 2041
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Contact the study team to confirm eligibility.
Study Completion
January 4, 2041
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
February 9, 2021
Record last verified: 2020-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: